Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Joshua S DavisAustralasian Society for Infectious Diseases Clinical Research Network

Abstract

In vitro laboratory and animal studies demonstrate a synergistic role for the combination of vancomycin and antistaphylococcal β-lactams for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Prospective clinical data are lacking. In this open-label, multicenter, clinical trial, adults with MRSA bacteremia received vancomycin 1.5 g intravenously twice daily and were randomly assigned (1:1) to receive intravenous flucloxacillin 2 g every 6 hours for 7 days (combination group) or no additional therapy (standard therapy group). Participants were stratified by hospital and randomized in permuted blocks of variable size. Randomization codes were kept in sealed, sequentially numbered, opaque envelopes. The primary outcome was the duration of MRSA bacteremia in days. We randomly assigned 60 patients to receive vancomycin (n = 29), or vancomycin plus flucloxacillin (n = 31). The mean duration of bacteremia was 3.00 days in the standard therapy group and 1.94 days in the combination group. According to a negative binomial model, the mean time to resolution of bacteremia in the combination group was 65% (95% confidence interval, 41%-102%; P = .06) that in the standard therapy group. There was no difference in the secondary en...Continue Reading

References

Jun 1, 1990·Antimicrobial Agents and Chemotherapy·P M Small, H F Chambers
Aug 17, 1999·Journal of Clinical Microbiology·F G O'BrienW B Grubb
Feb 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Pauline E. GosdenMichael R. Millar
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Nov 8, 2005·Internal Medicine Journal·D H Mitchell, B P Howden
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael J Rybak
Apr 19, 2006·The Medical Journal of Australia·Graeme R NimmoMary-Louise McLaws
Aug 4, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeffrey C HagemanUNKNOWN Infectious Diseases Society of America Emerging Infections Network
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Jun 6, 2007·Expert Review of Anti-infective Therapy·Stan Deresinski
Jul 27, 2007·Nature Clinical Practice. Nephrology·Tobin HoppesAlan Segal
Oct 18, 2007·JAMA : the Journal of the American Medical Association·R Monina KlevensUNKNOWN Active Bacterial Core surveillance (ABCs) MRSA Investigators
Feb 12, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveHelen W Boucher
Oct 8, 2009·The Medical Journal of Australia·John D TurnidgeUNKNOWN Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Abhay DhandGeorge Sakoulas
Dec 1, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Sudhakar Rao ChallagundlaChris Isles
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Thomas J DilworthRenée-Claude Mercier
Nov 26, 2013·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jessica K OrtwineMichael J Rybak
Dec 4, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·George SakoulasVictor Nizet
Feb 3, 2015·Seminars in Respiratory and Critical Care Medicine·J S DavisS Y C Tong
Feb 3, 2015·Seminars in Respiratory and Critical Care Medicine·Natasha E HolmesSebastiaan J van Hal

❮ Previous
Next ❯

Citations

Nov 14, 2015·The Journal of Antimicrobial Chemotherapy·Ravina KullarSebastiaan J van Hal
May 22, 2016·Infectious Disease Clinics of North America·Marisa HolubarStan Deresinski
Oct 6, 2016·Intensive Care Medicine·José-Artur Paiva, Philippe Eggimann
Feb 17, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Warren E RoseGeorge Sakoulas
Oct 19, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S RiegA Kaasch
Dec 30, 2016·Infection & chemotherapy·Eun Ju Choo, Henry F Chambers
Nov 9, 2017·Expert Opinion on Pharmacotherapy·Carlota GudiolJordi Carratalà
Aug 30, 2017·Journal of Pharmacy Practice·Gary FongAmelia K Sofjan
Sep 12, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas L HollandVance G Fowler
Oct 16, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sarah B DoernbergUNKNOWN Antibacterial Resistance Leadership Group
Jun 1, 2018·Nature Reviews. Disease Primers·Andie S LeeStephan Harbarth
Oct 20, 2019·The Journal of Infectious Diseases·Laura A GallagherJames P O'Gara
Apr 1, 2016·Trials·Steven Y C TongUNKNOWN CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network
Jan 9, 2020·Microbial Genomics·Stefano G GiulieriDeborah A Williamson
Feb 12, 2020·JAMA : the Journal of the American Medical Association·Steven Y C TongUNKNOWN Australasian Society for Infectious Diseases Clinical Research Network
Feb 12, 2020·JAMA : the Journal of the American Medical Association·Tejal N Gandhi, Preeti N Malani
Aug 20, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Hamideh Mohammadi-BerenjestanakiEzzat Allah Ghaemi
Oct 23, 2019·Antimicrobial Agents and Chemotherapy·Chang Kyung KangUNKNOWN Korea Infectious Diseases (KIND) Study Group
Apr 22, 2020·Antimicrobial Agents and Chemotherapy·Kyle C MolinaDouglas N Fish
Aug 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas L Holland, Joshua S Davis
Jul 16, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Steven Y C Tong, Joshua S Davis
Mar 24, 2018·Drugs·A J HeffernanJ A Roberts
Feb 10, 2019·Nature Reviews. Microbiology·Nicholas A TurnerVance G Fowler
Jan 13, 2017·The Journal of Infectious Diseases·Arnold S Bayer, Yan Q Xiong
Jul 5, 2018·JAMA : the Journal of the American Medical Association·Andrew WangVivian H Chu
Jun 14, 2020·Pharmacotherapy·Pramodini B Kale-PradhanMichael J Rybak
Nov 23, 2016·Current Infectious Disease Reports·Kyle C Molina, Vanthida Huang
Jul 10, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George SakoulasVictor Nizet
Jul 14, 2018·Journal of Clinical Pharmacy and Therapeutics·Paul O LewisDavid B Cluck
Aug 16, 2017·Critical Care : the Official Journal of the Critical Care Forum·Ali HassounBruce Friedman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.